Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (561)	2/16/1999 11:32:00 PM
From: 5,17,37,5,101,...	Respond to of 1073

Yes, I know about Recap's failings. I wrote you prematurely before checking OSIP web site which confirms PII for CP drug. Sorry, forgot to do my homework. Hey, it was a Friday night and I had a little gin. Well, even so. IMCL C225 is in PIII and so far no side effects and high cure rate. It seems that EGFr is very effective, small molecule or large. Small molecule may be more effective against other forms of cancer; who can say really? Investors don't seem to like OSIP as much, but most small biotechs are out of favor regardless. I may diversify a bit into OSIP because of its prospects; I respect Pfizer. Later, Jackson